Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (211-220 of 387) with videos related to

Pageof 39
Sort By:
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosisS Vincent Rajkumar, Ruben A Mesa, Rafael Fonseca, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Mayo Clinic Proceedings|January 17, 2003
Review of 1027 patients with newly diagnosed multiple myelomaRobert A Kyle, Morie A Gertz, Thomas E Witzig, et al.
The Journal of Experimental Medicine|November 3, 2010
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signalingJoanne M Hildebrand, Zhenghua Luo, Michelle K Manske, et al.
Blood Neoplasia|July 30, 2025
Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408Frederique St-Pierre, Stephen M Broski, Zequn Sun, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 22, 2010
Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphomaJennifer L Kelly, Anne J Novak, Zachary S Fredericksen, et al.
British Journal of Haematology|August 8, 2006
Absolute lymphocyte count predicts overall survival in follicular lymphomasMustaqeem Siddiqui, Kay Ristow, Svetomir N Markovic, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 23, 2012
A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 regionJames R Cerhan, Zachary S Fredericksen, Anne J Novak, et al.
The Lancet. Haematology|May 30, 2020
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trialGita Thanarajasingam, John P Leonard, Thomas E Witzig, et al.
Pageof 39

Showing results (211-220 of 387) with videos related to

Sort By:
Pageof 39
Mayo Clinic Proceedings|January 17, 2003
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myelomaShaji Kumar, Morie A Gertz, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosisS Vincent Rajkumar, Ruben A Mesa, Rafael Fonseca, et al.
Seminars in Oncology|February 1, 2017
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaLeo I Gordon, Thomas E Witzig, Greg A Wiseman, et al.
Mayo Clinic Proceedings|January 17, 2003
Review of 1027 patients with newly diagnosed multiple myelomaRobert A Kyle, Morie A Gertz, Thomas E Witzig, et al.
The Journal of Experimental Medicine|November 3, 2010
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signalingJoanne M Hildebrand, Zhenghua Luo, Michelle K Manske, et al.
Blood Neoplasia|July 30, 2025
Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408Frederique St-Pierre, Stephen M Broski, Zequn Sun, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 22, 2010
Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphomaJennifer L Kelly, Anne J Novak, Zachary S Fredericksen, et al.
British Journal of Haematology|August 8, 2006
Absolute lymphocyte count predicts overall survival in follicular lymphomasMustaqeem Siddiqui, Kay Ristow, Svetomir N Markovic, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 23, 2012
A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 regionJames R Cerhan, Zachary S Fredericksen, Anne J Novak, et al.
The Lancet. Haematology|May 30, 2020
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trialGita Thanarajasingam, John P Leonard, Thomas E Witzig, et al.
Pageof 39